Marksans Pharma gets UK MHRA nod for Bells Healthcare All in One Oral Solution
Marksans will manufacture the products at its UK MHRA approved facility Bell Sons and Co. (Druggists) Limited in UK.
Mumbai: Marksans Pharma Limited today announced that UK MHRA has granted market authorisation to the company's wholly owned subsidiary Bell Sons & Co. (Druggists) Limited for Bells Healthcare All in One Oral Solution. Each 20 ml dose contains Paracetamol Ph. Eur. 500.0 mg, Guaifenesin Ph. Eur. 200.0 mg andPhenylephrine Hydrochloride Ph. Eur. 10.0 mg. Therapeutic use of the product is...
Mumbai: Marksans Pharma Limited today announced that UK MHRA has granted market authorisation to the company's wholly owned subsidiary Bell Sons & Co. (Druggists) Limited for Bells Healthcare All in One Oral Solution.
Each 20 ml dose contains Paracetamol Ph. Eur. 500.0 mg, Guaifenesin Ph. Eur. 200.0 mg andPhenylephrine Hydrochloride Ph. Eur. 10.0 mg.
Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs.
This is the first generic approval by UK MHRA for the product.
Marksans will manufacture the products at its UK MHRA approved facility Bell Sons & Co. (Druggists) Limited in UK.
Read also: Marksans Pharma Cetirizine Hydrochloride Tablets get USFDA okay
Marksans Pharma, headquartered at Mumbai (India) is a global pharmaceutical company.
The company's key focus areas lie in the OTC & prescription drugs that have wide-ranging applications across fields like Oncology, Gastroenterology, Antidiabetic, Antibiotics, Cardiovascular, Pain Management, Gynaecology, among others.
Read also: UK MHRA okays Marksans Pharma anti-diarrhoea drug Loperamide
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd